The Spanish company, nLife Therapeutics, specializes in creating pharmaceutical products that use cell-specific delivery of nucleic acids to target central nervous system and neuromuscular disorders. Their innovative treatments have the potential to modify diseases that currently have no viable treatment options. By delivering conjugated nucleic acids with small chemicals to selected neurons through a single intra-nasal application, nLife Therapeutics is able to target previously un-druggable proteins. They have already launched siRNA based programs for Parkinson's disease, Morbid Obesity, and Major Depressive Disorder, and are now focused on advancing clinical trials for their treatments.